Of interest, a post‐hoc analysis of COMPACT found that, among patients who were using the IV formulation of C1INH as routine prophylaxis pre‐study, switching to the SC formulation of C1INH produced a clinically meaningful ∼50% mean reduction in HAE attacks.32 The gene discussed is SERPING1; the disease is hereditary angioedema.